Michelle L. Basil
Net Worth

Last updated:

What is Michelle L. Basil net worth?

The estimated net worth of Ms. Michelle L. Basil is at least $17,957,627 as of 16 May 2024. She owns shares worth $1,625,912 as insider, has earned $10,621,745 from insider trading and has received compensation worth at least $5,709,970 in Haemonetics Corporation.

What is the salary of Michelle L. Basil?

Ms. Michelle L. Basil salary is $815,710 per year as Executive Vice President, Gen. Counsel & Sec. in Haemonetics Corporation.

How old is Michelle L. Basil?

Ms. Michelle L. Basil is 53 years old, born in 1972.

What stocks does Michelle L. Basil currently own?

As insider, Ms. Michelle L. Basil owns shares in one company:

Company Title Shares Price per share Total value
Haemonetics Corporation (HAE) Executive Vice President, Gen. Counsel & Sec. 30,425 $53.44 $1,625,912

What does Haemonetics Corporation do?

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE logo
HAE
Haemonetics Corporation
$53.44

Michelle L. Basil insider trading

Haemonetics Corporation

Ms. Michelle L. Basil has made 30 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently she sold 985 units of HAE stock worth $94,698 on 16 May 2024.

The largest trade she's ever made was exercising 27,769 units of HAE stock on 15 Sep 2022. As of 16 May 2024 she still owns at least 30,425 units of HAE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 985 $96.14 $94,698
Sale
Common Stock 180 $80.39 $14,470
Option
Common Stock 4,213 $41.64 $175,429
Option
Common Stock 1,011 $56.57 $57,192
Option
Non-qualified Stock Option (Right to Buy) 1,011 $56.57 $57,192
Option
Non-qualified Stock Option (Right to Buy) 4,213 $41.64 $175,429
Sale
Common Stock 11,448 $78.36 $897,065
Option
Common Stock 3,464 $38.43 $133,122
Sale
Common Stock 27,769 $77.76 $2,159,317
Option
Non-qualified Stock Option (Right to Buy) 11,154 $38.43 $428,648
Option
Non-qualified Stock Option (Right to Buy) 14,231 $41.64 $592,579
Option
Non-qualified Stock Option (Right to Buy) 3,173 $56.57 $179,497
Option
Common Stock 11,154 $38.43 $428,648
Option
Common Stock 14,231 $41.64 $592,579
Option
Common Stock 3,173 $56.57 $179,497
Sale
Common Stock 6,029 $78.5 $473,277
Sale
Common Stock 277 $62.6 $17,340
Sale
Common Stock 3,258 $59.1 $192,548
Sale
Common Stock 196 $56.1 $10,996
Sale
Common Stock 120 $71.93 $8,632
Sale
Common Stock 195 $59.87 $11,675
Sale
Common Stock 442 $55.09 $24,350
Sale
Common Stock 220 $55.19 $12,142
Sale
Common Stock 204 $55.97 $11,418
Sale
Common Stock 385 $120.07 $46,227
Sale
Common Stock 181 N/A N/A
Sale
Common Stock 13,436 $61.16 $821,746
Sale
Common Stock 13,436 $91.27 $1,226,263
Sale
Common Stock 10,578 $87.71 $927,796
Sale
Common Stock 203 $89.29 $18,126
Sale
Common Stock 687 $97.03 $66,660
Sale
Common Stock 203 $100.44 $20,389
Sale
Common Stock 395 $98 $38,710
Sale
Common Stock 10,633 $123.51 $1,313,314
Sale
Common Stock 8,883 $122.34 $1,086,746
Sale
Common Stock 231 $109.37 $25,264
Option
Non-qualified Stock Option (Right to Buy) 4,872 $38.43 $187,231
Option
Common Stock 4,872 $38.43 $187,231
Sale
Common Stock 7,187 $103.44 $743,423
Option
Common Stock 6,148 $41.64 $256,003
Option
Non-qualified Stock Option (Right to Buy) 6,148 $41.64 $256,003
Sale
Common Stock 6,148 $41.64 $256,003
Sale
Common Stock 391 $83.57 $32,676
Sale
Common Stock 457 $92.73 $42,378
Sale
Common Stock 389 $72.23 $28,097

Haemonetics key executives

Haemonetics Corporation executives and other stock owners filed with the SEC: